Drug discovery and development

• For Researchers
• Science & Technology

Delivering the future of paediatric brain tumour therapy

Dr Lisa Ruff tells us why drug delivery is so important for the treatment of paediatric brain tumours – and why hydrogels could be key to a breakthrough… Dr Lisa Ruff tells us why drug delivery is so important for the treatment of paediatric brain tumours – and why hydrogels could be key to a breakthrough…

7 October 2021

• Health & Medicine
• Science & Technology

Cancer Research UK reports record levels of investment in its spinouts

The charity’s commercial arm saw the amount of money from both internal and external sources invested in its spinouts more than double in the last year. The charity’s commercial arm saw the amount of money from both internal and external sources invested in its spinouts more than double in the last year.

24 August 2021

• Health & Medicine
• Science & Technology

Innovative cancer spinouts: 3 new projects get green light

The spin out companies are engineering viruses to seek and destroy cancer cells and using bacteria to break down the physical defences of tumours. The spin out companies are engineering viruses to seek and destroy cancer cells and using bacteria to break down the physical defences of tumours.

13 August 2021

• Health & Medicine
• Science & Technology

Scientists trial new way to boost CAR T-cell therapy

Cancer Research UK is collaborating with Aleta Biotherapeutics (Aleta) to trial a new therapy that ‘reboots’ a treatment for some people with blood cancer whose cancer starts to come back. Cancer Research UK is collaborating with Aleta Biotherapeutics (Aleta) to trial a new therapy that ‘reboots’ a treatment for some people with blood cancer whose cancer starts to come back.

23 June 2021

• Science & Technology

Scientists developing new class of drug for leukaemia

Scientists are developing a new drug for treating acute myeloid leukaemia (AML), a type of blood cancer that affects around 3,100 people in the UK each year.  Scientists are developing a new drug for treating acute myeloid leukaemia (AML), a type of blood cancer that affects around 3,100 people in the UK each year. 

27 April 2021

• Science & Technology

Cancer Research UK and AstraZeneca’s new antibody maturation technique yields high-affinity Arginase 2 antibody

Researchers in Cambridge have pioneered the development of an innovative affinity maturation technique to generate high-affinity antibody against Arginase 2. Researchers in Cambridge have pioneered the development of an innovative affinity maturation technique to generate high-affinity antibody against Arginase 2.

3 September 2020

• Science & Technology

First-in-human trial for new lung cancer immunotherapy

Cancer Research UK and VOLT, announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lung cancer Cancer Research UK and VOLT, announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lung cancer

17 December 2019

• Health & Medicine
• Science & Technology

Blocking a survival mechanism could tackle melanoma treatment resistance

Researchers have demonstrated an approach which, used in parallel with existing treatments, wipes out the ‘survival system’ of cancer cells. Researchers have demonstrated an approach which, used in parallel with existing treatments, wipes out the ‘survival system’ of cancer cells.

14 November 2019

• Science & Technology
• Health & Medicine

Trial to test new treatment combination for children and adults with leukaemia

A clinical trial testing a new treatment combination in patients with leukaemia launches through the Combinations Alliance today. A clinical trial testing a new treatment combination in patients with leukaemia launches through the Combinations Alliance today.

30 May 2018

• Science & Technology

Cancer Research UK and the Institute of Cancer Research, London, join forces with Merck in new drug discovery alliance

Cancer Research UK and The Institute of Cancer Research, London announce a multi-project collaboration and licensing deal with Merck. Cancer Research UK and The Institute of Cancer Research, London announce a multi-project collaboration and licensing deal with Merck.

17 January 2018